

Hendrick Simon Schaaf

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/361501/publications.pdf>

Version: 2024-02-01

174
papers

10,475
citations

31976

53
h-index

36028

97
g-index

176
all docs

176
docs citations

176
times ranked

7348
citing authors

#	ARTICLE	IF	CITATIONS
1	Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. <i>Clinical Infectious Diseases</i> , 2016, 63, e147-e195.	5.8	916
2	Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. <i>Lancet, The</i> , 2010, 375, 1830-1843.	13.7	866
3	The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , the, 2017, 5, 291-360.	10.7	459
4	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. <i>PLoS Medicine</i> , 2012, 9, e1001300.	8.4	430
5	Childhood Pulmonary Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1078-1090.	5.6	326
6	Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, e93-e142.	5.6	282
7	Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. <i>Clinical Infectious Diseases</i> , 2016, 63, 853-867.	5.8	237
8	A Refined Symptom-Based Approach to Diagnose Pulmonary Tuberculosis in Children. <i>Pediatrics</i> , 2006, 118, e1350-e1359.	2.1	235
9	Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. <i>European Respiratory Journal</i> , 2013, 42, 169-179.	6.7	226
10	The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. <i>Vaccine</i> , 2007, 25, 14-18.	3.8	220
11	Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. <i>BMJ: British Medical Journal</i> , 2007, 334, 136.	2.3	199
12	Evaluation of Young Children in Contact With Adult Multidrug-Resistant Pulmonary Tuberculosis: A 30-Month Follow-up. <i>Pediatrics</i> , 2002, 109, 765-771.	2.1	179
13	Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. <i>Lancet Infectious Diseases, The</i> , 2012, 12, 449-456.	9.1	164
14	A proposed radiological classification of childhood intra-thoracic tuberculosis. <i>Pediatric Radiology</i> , 2004, 34, 886-894.	2.0	163
15	The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. <i>Lancet, The</i> , 2020, 395, 973-984.	13.7	160
16	Clinical presentation and outcome of Tuberculosis in Human Immunodeficiency Virus infected children on anti-retroviral therapy. <i>BMC Pediatrics</i> , 2008, 8, 1.	1.7	147
17	Isoniazid pharmacokinetics in children treated for respiratory tuberculosis. <i>Archives of Disease in Childhood</i> , 2005, 90, 614-618.	1.9	141
18	MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. <i>International Journal of Infectious Diseases</i> , 2020, 92, S15-S25.	3.3	126

#	ARTICLE	IF	CITATIONS
19	Isoniazid Plasma Concentrations in a Cohort of South African Children with Tuberculosis: Implications for International Pediatric Dosing Guidelines. <i>Clinical Infectious Diseases</i> , 2009, 48, 1547-1553.	5.8	125
20	Tuberculosis at extremes of age. <i>Respirology</i> , 2010, 15, 747-763.	2.3	123
21	Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases. <i>BMC Infectious Diseases</i> , 2007, 7, 140.	2.9	120
22	Tuberculous Lymphadenitis as a Cause of Persistent Cervical Lymphadenopathy in Children From a Tuberculosis-Endemic Area. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 142-146.	2.0	101
23	Preventive Therapy for Child Contacts of Multidrug-Resistant Tuberculosis: A Prospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2013, 57, 1676-1684.	5.8	101
24	Hearing loss in patients on treatment for drug-resistant tuberculosis. <i>European Respiratory Journal</i> , 2012, 40, 1277-1286.	6.7	96
25	ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. <i>European Respiratory Journal</i> , 2014, 44, 811-815.	6.7	96
26	Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis. <i>PLoS Medicine</i> , 2018, 15, e1002591.	8.4	96
27	Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. <i>Archives of Disease in Childhood</i> , 2003, 88, 1106-1111.	1.9	94
28	The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. <i>Lancet Respiratory Medicine</i> , 2019, 7, 820-826.	10.7	92
29	Short Intensified Treatment in Children with Drug-susceptible Tuberculous Meningitis. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 248-252.	2.0	91
30	Outcome of HIV infected children with culture confirmed tuberculosis. <i>Archives of Disease in Childhood</i> , 2005, 90, 1171-1174.	1.9	90
31	Culture-Confirmed Multidrug-Resistant Tuberculosis in Children: Clinical Features, Treatment, and Outcome. <i>Clinical Infectious Diseases</i> , 2012, 54, 157-166.	5.8	89
32	High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. <i>Thorax</i> , 2014, 69, 458-464.	5.6	89
33	Childhood Tuberculosis: An Emerging and Previously Neglected Problem. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 727-749.	5.1	88
34	Comparison of Diagnostic Criteria of Tuberculous Meningitis in Human Immunodeficiency Virus-Infected and Uninfected Children. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 65-69.	2.0	87
35	A Proposed Comprehensive Classification of Tuberculosis Disease Severity in Children. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 347-352.	2.0	85
36	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 265-275.	10.7	80

#	ARTICLE	IF	CITATIONS
37	Beijing and Haarlem Genotypes Are Overrepresented among Children with Drug-Resistant Tuberculosis in the Western Cape Province of South Africa. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3539-3543.	3.9	77
38	Management of multidrug-resistant tuberculosis in children: a survival guide for paediatricians. <i>Paediatric Respiratory Reviews</i> , 2011, 12, 31-38.	1.8	75
39	Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis. <i>BMC Medicine</i> , 2009, 7, 19.	5.5	73
40	Surveillance of Antituberculosis Drug Resistance Among Children From the Western Cape Province of South Africa—An Upward Trend. <i>American Journal of Public Health</i> , 2009, 99, 1486-1490.	2.7	71
41	Hearing loss in children treated for multidrug-resistant tuberculosis. <i>Journal of Infection</i> , 2013, 66, 320-329.	3.3	71
42	Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges. <i>European Respiratory Journal</i> , 2016, 48, 938-943.	6.7	71
43	Symptom-Based Screening of Child Tuberculosis Contacts: Improved Feasibility in Resource-Limited Settings. <i>Pediatrics</i> , 2008, 121, e1646-e1652.	2.1	67
44	Tuberculosis in Children. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014, 4, a017855-a017855.	6.2	66
45	Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 711-720.	9.1	66
46	Twice weekly vs. daily chemotherapy for childhood tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2000, 19, 405-410.	2.0	64
47	Recurrent Culture-Confirmed Tuberculosis in Human Immunodeficiency Virus-Infected Children. <i>Pediatric Infectious Disease Journal</i> , 2005, 24, 685-691.	2.0	64
48	Caring for Children with Drug-Resistant Tuberculosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 953-964.	5.6	63
49	Pharmacokinetics and Safety of Moxifloxacin in Children With Multidrug-Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2015, 60, 549-556.	5.8	62
50	New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1300-1310.	5.6	61
51	Childhood drug-resistant tuberculosis in the Western Cape Province of South Africa. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2006, 95, 523-528.	1.5	58
52	Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. <i>South African Medical Journal</i> , 2012, 102, 363.	0.6	56
53	Paediatric use of second-line anti-tuberculosis agents: A review. <i>Tuberculosis</i> , 2012, 92, 9-17.	1.9	56
54	Xpert MTB/RIF on Stool Is Useful for the Rapid Diagnosis of Tuberculosis in Young Children With Severe Pulmonary Disease. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, 837-843.	2.0	56

#	ARTICLE	IF	CITATIONS
55	Transmission of multidrug-resistant tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2000, 19, 695-700.	2.0	54
56	Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1339-1349.	3.0	53
57	Linezolid for the treatment of drug-resistant tuberculosis in children: A review and recommendations. <i>Tuberculosis</i> , 2014, 94, 93-104.	1.9	51
58	Radiographic Signs and Symptoms in Children Treated for Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 237-240.	2.0	50
59	Multidrug- and Extensively Drug-resistant Tuberculosis in Africa and South America: Epidemiology, Diagnosis and Management in Adults and Children. <i>Clinics in Chest Medicine</i> , 2009, 30, 667-683.	2.1	50
60	Failure of Chemoprophylaxis With Standard Antituberculosis Agents in Child Contacts of Multidrug-Resistant Tuberculosis Cases. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 1142-1146.	2.0	49
61	Minimal inhibitory concentration of isoniazid in isoniazid-resistant <i>Mycobacterium tuberculosis</i> isolates from children. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2007, 26, 203-205.	2.9	48
62	Management of children exposed to multidrug-resistant <i>Mycobacterium tuberculosis</i> . <i>Lancet Infectious Diseases</i> , The, 2012, 12, 469-479.	9.1	48
63	Impact of Drug Resistance on Clinical Outcome in Children With Tuberculous Meningitis. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 711-716.	2.0	47
64	Drug-resistant Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 501-505.	2.0	46
65	Optimizing the Detection of Recent Tuberculosis Infection in Children in a High Tuberculosis and HIV Burden Setting. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 820-830.	5.6	46
66	LONG-TERM LINEZOLID TREATMENT IN A YOUNG CHILD WITH EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 748-750.	2.0	45
67	Detecting Tuberculosis Infection in HIV-infected Children. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, e111-e118.	2.0	44
68	Culture-positive tuberculosis in human immunodeficiency virus type 1-infected children. <i>Pediatric Infectious Disease Journal</i> , 1998, 17, 599-604.	2.0	42
69	Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: Combined data from two prospective observational studies. <i>PLoS Medicine</i> , 2019, 16, e1002789.	8.4	41
70	Evaluation of young children in household contact with adult multidrug-resistant pulmonary tuberculosis cases. <i>Pediatric Infectious Disease Journal</i> , 1999, 18, 494-500.	2.0	41
71	Consensus Statement on Research Definitions for Drug-Resistant Tuberculosis in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2013, 2, 100-109.	1.3	40
72	A rapid method for detection of five known mutations associated with aminoglycoside-induced deafness. <i>BMC Medical Genetics</i> , 2009, 10, 2.	2.1	39

#	ARTICLE	IF	CITATIONS
73	Old and new drugs for the treatment of tuberculosis in children. <i>Paediatric Respiratory Reviews</i> , 2007, 8, 134-141.	1.8	37
74	Levofloxacin Population Pharmacokinetics in South African Children Treated for Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	37
75	Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP). <i>Trials</i> , 2018, 19, 693.	1.6	36
76	Opportunities for chemoprophylaxis in children with culture-confirmed tuberculosis. <i>Annals of Tropical Paediatrics</i> , 2011, 31, 301-310.	1.0	35
77	Assessing the impact of multidrug-resistant tuberculosis in children: an exploratory qualitative study. <i>BMC Infectious Diseases</i> , 2014, 14, 426.	2.9	34
78	Clinical features and outcome in children admitted to a TB hospital in the Western Cape--the influence of HIV infection and drug resistance. <i>South African Medical Journal</i> , 2005, 95, 602-6.	0.6	31
79	Clinicoradiologic Response of Neurologic Tuberculous Mass Lesions in Children Treated With Thalidomide. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, 214-218.	2.0	29
80	Adverse effects of oral second-line antituberculosis drugs in children. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1369-1381.	2.4	29
81	Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1042-1051.	9.1	28
82	Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3237-3246.	3.0	26
83	Risk factors for infection and disease in child contacts of multidrug-resistant tuberculosis: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2013, 13, 392.	2.9	25
84	Managing multidrug-resistant tuberculosis in children. <i>Current Opinion in Infectious Diseases</i> , 2014, 27, 211-219.	3.1	25
85	Abdominal Tuberculosis in Children: Challenges, Uncertainty, and Confusion. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 218-227.	1.3	25
86	Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2018, 67, 1777-1780.	5.8	24
87	Human immunodeficiency virus infection in children hospitalised with tuberculosis. <i>Annals of Tropical Paediatrics</i> , 2002, 22, 115-123.	1.0	22
88	The Impact of a Change in Bacille Calmette-Gu??rin Vaccine Policy on Tuberculosis Incidence in Children in Cape Town, South Africa. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 1167-1172.	2.0	22
89	The value of transcranial Doppler imaging in children with tuberculous meningitis. <i>Child's Nervous System</i> , 2014, 30, 1711-1716.	1.1	22
90	A critical look at the diagnostic value of culture-confirmation in childhood tuberculosis. <i>Journal of Infection</i> , 2006, 53, 364-369.	3.3	21

#	ARTICLE	IF	CITATIONS
91	Absence of an Association Between Mycobacterium tuberculosis Genotype and Clinical Features in Children With Tuberculous Meningitis. <i>Pediatric Infectious Disease Journal</i> , 2007, 26, 13-18.	2.0	21
92	Antituberculosis drugs in children. <i>Clinical Pharmacology and Therapeutics</i> , 2015, 98, 252-265.	4.7	21
93	Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach. <i>Indian Journal of Pediatrics</i> , 2019, 86, 717-724.	0.8	21
94	Probable Levofloxacin-associated Secondary Intracranial Hypertension in a Child With Multidrug-resistant Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 706-708.	2.0	20
95	Antimicrobial resistance in tuberculosis: an international perspective. <i>Expert Review of Anti-Infective Therapy</i> , 2006, 4, 759-766.	4.4	19
96	Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 662-664.	10.7	19
97	Multidrug-resistant tuberculosis in children and adolescents: current strategies for prevention and treatment. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 221-237.	2.5	19
98	PYRAZINAMIDE PLASMA CONCENTRATIONS IN YOUNG CHILDREN WITH TUBERCULOSIS. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 262-265.	2.0	18
99	Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 233-244.	3.1	18
100	Tuberculosis, COVID-19 and hospital admission: Consensus on pros and cons based on a review of the evidence. <i>Pulmonology</i> , 2021, 27, 248-256.	2.1	18
101	Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 124, S90-S103.	3.3	18
102	Pharmacokinetics and Safety of Ofloxacin in Children with Drug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6073-6079.	3.2	17
103	Drug-resistant tuberculosis and advances in the treatment of childhood tuberculosis. <i>Pneumonia (Nathan Qld)</i> , 2016, 8, 20.	6.1	16
104	Adolescents and young adults: a neglected population group for tuberculosis surveillance. <i>European Respiratory Journal</i> , 2018, 51, 1800176.	6.7	16
105	Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	16
106	Specimen Pooling as a Diagnostic Strategy for Microbiologic Confirmation in Children with Intrathoracic Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, e128-e131.	2.0	16
107	Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant Tuberculosis. <i>Emerging Infectious Diseases</i> , 2019, 25, 441-450.	4.3	16
108	Child health and tuberculosis. <i>Lancet Respiratory Medicine</i> , 2014, 2, 254-256.	10.7	15

#	ARTICLE	IF	CITATIONS
109	Complementary surveillance strategies are needed to better characterise the epidemiology, care pathways and treatment outcomes of tuberculosis in children. <i>BMC Public Health</i> , 2018, 18, 397.	2.9	14
110	Pharmacokinetics, Safety, and Dosing of Novel Pediatric Levofloxacin Dispersible Tablets in Children with Multidrug-Resistant Tuberculosis Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	14
111	Aminoglycoside-induced hearing loss: South Africans at risk. <i>South African Medical Journal</i> , 2009, 99, 440-1.	0.6	14
112	Multidrug-Resistant Tuberculosis of the Spine in Children—Characteristics from a High Burden Setting. <i>Journal of Tropical Pediatrics</i> , 2012, 58, 341-347.	1.5	13
113	The safety and tolerability of the second-line injectable antituberculosis drugs in children. <i>Expert Opinion on Drug Safety</i> , 2016, 15, 1491-1500.	2.4	13
114	The impact of drug resistance on the risk of tuberculosis infection and disease in child household contacts: a cross sectional study. <i>BMC Infectious Diseases</i> , 2017, 17, 593.	2.9	13
115	Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment of Rifampicin-Resistant Tuberculosis in Children. <i>Clinical Infectious Diseases</i> , 2022, 74, 1372-1381.	5.8	13
116	Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities. <i>Pathogens</i> , 2022, 11, 381.	2.8	13
117	Pediatric TB: issues related to current and future treatment options. <i>Future Microbiology</i> , 2009, 4, 661-675.	2.0	12
118	Overview of extrapulmonary tuberculosis in adults and children. , 2009, , 377-390.		12
119	Acquired Drug Resistance During Inadequate Therapy in A Young Child with Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 883-885.	2.0	12
120	Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 589-598.	1.8	12
121	Tuberculosis treatment in children: The changing landscape. <i>Paediatric Respiratory Reviews</i> , 2020, 36, 33-43.	1.8	12
122	Management of children with tuberculosis admitted to a pediatric intensive care unit. <i>Pediatric Infectious Disease Journal</i> , 1998, 17, 403-407.	2.0	12
123	Drug-resistant tuberculosis in children. <i>South African Medical Journal</i> , 2007, 97, 995-7.	0.6	12
124	Nutritional status and its response to treatment of children, with and without HIV infection, hospitalized for the management of tuberculosis. <i>Paediatrics and International Child Health</i> , 2012, 32, 74-81.	1.0	11
125	Drug-Resistant Tuberculosis Transmission and Resistance Amplification within Families. <i>Emerging Infectious Diseases</i> , 2012, 18, 1342-5.	4.3	11
126	Priority Activities in Child and Adolescent Tuberculosis to Close the Policy-Practice Gap in Low- and Middle-Income Countries. <i>Pathogens</i> , 2022, 11, 196.	2.8	11

#	ARTICLE	IF	CITATIONS
127	Tuberculous Pericardial Effusions in Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2018, 7, 346-349.	1.3	10
128	Isoniazid preventive therapy in HIV-infected and -uninfected children (0 - 14 years). <i>South African Medical Journal</i> , 2013, 103, 714.	0.6	9
129	HIV transmission between two siblings in Africa. <i>Aids</i> , 2000, 14, 896.	2.2	9
130	The Role of Xpert MTB/RIF Ultra in Diagnosing Pulmonary Tuberculosis in Children. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 1464-1465.	5.6	8
131	Acceptability of a Novel Levofloxacin Dispersible Tablet Formulation in Young Children Exposed to Multidrug-resistant Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 608-610.	2.0	8
132	Pharmacokinetics and Safety of Bedaquiline in Human Immunodeficiency Virus (HIV)-Positive and Negative Older Children and Adolescents With Rifampicin-Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2022, 75, 1772-1780.	5.8	8
133	Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0214421.	3.2	8
134	A randomized controlled trial of intermittent compared with daily cotrimoxazole preventive therapy in HIV-infected children. <i>Aids</i> , 2010, 24, 2225-2232.	2.2	7
135	Effect of Coadministration of Lidocaine on the Pain and Pharmacokinetics of Intramuscular Amikacin in Children With Multidrug-Resistant Tuberculosis: A Randomized Crossover Trial. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, 1199-1203.	2.0	7
136	Population Pharmacokinetics and Dosing of Ethionamide in Children with Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	7
137	Retooling Existing Tuberculosis Drugs for Children. <i>Clinical Infectious Diseases</i> , 2013, 56, 167-168.	5.8	6
138	Successful Treatment of a Child With Extensively Drug-Resistant Tuberculous Meningitis: Figure 1.. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2015, 4, e41-e44.	1.3	6
139	Abdominal Involvement in Children With Bacteriologically Confirmed Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 914-919.	2.0	6
140	Trends in Drug Resistance in Childhood Tuberculosis in Cape Town, South Africa. <i>Pediatric Infectious Disease Journal</i> , 2020, 39, 604-608.	2.0	6
141	Childhood Cancers Misdiagnosed as Tuberculosis in a High Tuberculosis Burden Setting. <i>Pediatric Infectious Disease Journal</i> , 2021, 40, 1076-1080.	2.0	6
142	Management of tuberculous meningitis in children. <i>Paediatrics and International Child Health</i> , 2021, 41, 231-236.	1.0	6
143	The Diagnostic Accuracy of Chest Radiographic Features for Pediatric Intrathoracic Tuberculosis. <i>Clinical Infectious Diseases</i> , 2022, 75, 1014-1021.	5.8	6
144	Preface. <i>Clinics in Chest Medicine</i> , 2009, 30, xiii-xviii.	2.1	5

#	ARTICLE	IF	CITATIONS
145	Toxicity and Tolerability of Fluoroquinolone-based Preventive Therapy for Childhood Contacts of Multidrug-resistant Tuberculosis. <i>Pediatric Infectious Disease Journal</i> , 2014, 33, 1098-1099.	2.0	5
146	The Impact of the Evolving Human Immunodeficiency Virus Response on the Epidemiology of Tuberculosis in South African Children and Adolescents. <i>Clinical Infectious Diseases</i> , 2021, 73, e967-e975.	5.8	5
147	Multidrug-Resistant Tuberculosis in Children: Recent Developments in Diagnosis, Treatment and Prevention. <i>Current Pediatrics Reports</i> , 2016, 4, 53-62.	4.0	4
148	Revisiting the mutant prevention concentration to guide dosing in childhood tuberculosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 1848-1857.	3.0	4
149	Culture-confirmed Tuberculosis in South African Infants Younger Than 3 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 351-354.	2.0	4
150	Multidrug-resistant tuberculosis in children. , 2009, , 532-538.		3
151	Induced sputum microbiology in confirming pulmonary tuberculosis in children [Editorial]. <i>International Journal of Tuberculosis and Lung Disease</i> , 2011, 15, 1139-1139.	1.2	3
152	Discordant Drug Susceptibility For Mycobacterium tuberculosis within Families. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 783-785.	2.0	3
153	Commentary: minimizing the risk of non-vertical, non-sexual HIV infection in children â€œ beyond mother to child transmission. <i>Journal of the International AIDS Society</i> , 2012, 15, 17377.	3.0	3
154	Pharmacokinetics and Drug-Drug Interactions of Abacavir and Lamuvudine Co-administered With Antituberculosis Drugs in HIV-Positive Children Treated for Multidrug-Resistant Tuberculosis. <i>Frontiers in Pharmacology</i> , 2021, 12, 722204.	3.5	3
155	Human immunodeficiency virus infection and child sexual abuse. <i>South African Medical Journal</i> , 2004, 94, 782-5.	0.6	3
156	Tuberculous Meningitis in Children: A Forgotten Public Health Emergency. <i>Frontiers in Neurology</i> , 2022, 13, 751133.	2.4	3
157	Fine Needle Aspiration Biopsy of Peripheral Lymph Nodes in Children: Practical Experience in a Tertiary Hospital. <i>Journal of Tropical Pediatrics</i> , 2020, 67, .	1.5	2
158	Positive <i>Mycobacterium tuberculosis</i> Gastric Lavage Cultures from Asymptomatic Children With Normal Chest Radiography. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021, 10, 502-508.	1.3	2
159	Challenges in childhood tuberculosis. , 0, , 234-262.		2
160	Nosocomial infections in HIV-infected and HIV-uninfected children hospitalised for tuberculosis. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2007, 49, 14-14e.	0.6	1
161	Childhood drug-resistant tuberculosis in the Western Cape Province of South Africa. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2006, 95, 523-528.	1.5	1
162	Radiology services for children in HIV- and TB-endemic regions: scope for greater collaboration between radiologists and clinicians caring for children. <i>Pediatric Radiology</i> , 2009, 39, 541-544.	2.0	1

#	ARTICLE	IF	CITATIONS
163	Tuberculosis drug therapy in children. , 2009, , 627-637.		1
164	Chapter 4: Isoniazid Pharmacokinetics and Efficacy in Adults and Children. Progress in Respiratory Research, 2011, , 25-31.	0.1	1
165	Epidemiology and management of childhood multidrug-resistant tuberculosis. Clinical Practice (London, England), 2012, 9, 701-713.	0.1	1
166	In Reply. Pediatric Infectious Disease Journal, 2014, 33, 993-994.	2.0	1
167	A new paradigm for multidrug-resistant tuberculosis?. International Journal of Tuberculosis and Lung Disease, 2014, 18, 884-884.	1.2	1
168	In Reply. Pediatric Infectious Disease Journal, 2014, 33, 1205-1206.	2.0	1
169	Adverse Events Associated With New Injectable-Free Multidrug-Resistant Tuberculosis Drug Regimens. Archivos De Bronconeumologia, 2020, 56, 823-825.	0.8	1
170	Intrathoracic tuberculosis in childrenThe most common clinical presentations. , 2009, , 361-363.		0
171	Management algorithms for paediatric tuberculosis. , 2009, , 323-331.		0
172	Adverse Events Associated With New Injectable-Free Multidrug-Resistant Tuberculosis Drug Regimens. Archivos De Bronconeumologia, 2020, 56, 823-825.	0.8	0
173	Update on multidrug-resistant tuberculosis in children. International Journal of Mycobacteriology, 2016, 5, S7.	0.6	0
174	UNSUSPECTED FATAL DRUG-RESISTANT TUBERCULOSIS IN A CLOSELY MONITORED CHILD: A PLEA FOR IMPROVED SOURCE-CASE TRACING AND DRUG SUSCEPTIBILITY TESTING. The Southern African Journal of Epidemiology & Infection: Official Journal of the Sexually Transmitted Diseases, Infectious Diseases and Epidemiological Societies of Southern Africa, 2010, 25, 30-32.	0.2	0